Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells

被引：14

作者：

Ivana, Tapuchova ^{[1
,2
]}

Robert, Pytlik ^{[4
]}

Pavel, Simara ^{[3
,4
]}

Lenka, Tesarova ^{[2
,3
]}

Irena, Koutna ^{[1
,2
,3
]}

机构：

[1] Masaryk Univ, Fac Sci, Dept Expt Biol, Kamenice 5, Brno 62500, Czech Republic

[2] St Annes Univ Hosp Brno, Int Clin Res Ctr, Pekarska 53, Brno 65691, Czech Republic

[3] Masaryk Univ, Fac Med, Dept Histol & Embryol, Karnenice 3, Brno 62500, Czech Republic

[4] Inst Hematol & Blood Transfus, Cell Therapy Dept, U Nemocnice 2094-1, Prague 12800 2, Czech Republic

来源：

TRANSPLANT IMMUNOLOGY | 2022年 / 71卷

关键词：

Virus-specific T cells; Herpesviruses; Adoptive transfer; Cytomegalovirus; Resistance; Interferon gamma; Immunotherapy; EPSTEIN-BARR-VIRUS; VARICELLA-ZOSTER-VIRUS; VERSUS-HOST-DISEASE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; SARCOMA-ASSOCIATED HERPESVIRUS; SEVERE VIRAL-INFECTIONS; RESISTANT CYTOMEGALOVIRUS; GANCICLOVIR-RESISTANT; RISK-FACTORS; IN-VITRO;

D O I：

10.1016/j.trim.2022.101539

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Herpesviruses can either cause primary infection or may get reactivated after both hematopoietic cell and solid organ transplantations. In general, viral infections increase post-transplant morbidity and mortality. Prophylactic, preemptive, or therapeutically administered antiviral drugs may be associated with serious side effects and may induce viral resistance. Virus-specific T cells represent a valuable addition to antiviral treatment, with high rates of response and minimal side effects. Even low numbers of virus-specific T cells manufactured by direct selection methods can reconstitute virus-specific immunity after transplantation and control viral replication. Virus-specific T cells belong to the advanced therapy medicinal products, and their production is regulated by appropriate legislation; also, strict safety regulations are required to minimize their side effects.

引用

页数：13

共 241 条

[1] Classification of HHV-6A and HHV-6B as distinct viruses [J].

Ablashi, Dharam ;

Agut, Henri ;

Alvarez-Lafuente, Roberto ;

Clark, Duncan A. ;

Dewhurst, Stephen ;

DiLuca, Dario ;

Flamand, Louis ;

Frenkel, Niza ;

Gallo, Robert ;

Gompels, Ursula A. ;

Hollsberg, Per ;

Jacobson, Steven ;

Luppi, Mario ;

Lusso, Paolo ;

Malnati, Mauro ;

Medveczky, Peter ;

Mori, Yasuko ;

Pellett, Philip E. ;

Pritchett, Joshua C. ;

Yamanishi, Koichi ;

Yoshikawa, Tetsushi .

ARCHIVES OF VIROLOGY, 2014, 159 (05) :863-870

[2] Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients [J].

Abraham, Allistair A. ;

John, Tami D. ;

Keller, Michael D. ;

Cruz, C. Russell N. ;

Salem, Baheyeldin ;

Roesch, Lauren ;

Liu, Hao ;

Hoq, Fahmida ;

Grilley, Bambi J. ;

Gee, Adrian P. ;

Dave, Hema ;

Jacobsohn, David A. ;

Krance, Robert A. ;

Shpall, Elizabeth J. ;

Martinez, Caridad A. ;

Hanley, Patrick J. ;

Bollard, Catherine M. .

BLOOD ADVANCES, 2019, 3 (14) :2057-2068

[3] Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes [J].

Ahlqvist, J ;

Fotheringham, J ;

Akhyani, N ;

Yao, K ;

Fogdell-Hahn, A ;

Jacobson, S .

JOURNAL OF NEUROVIROLOGY, 2005, 11 (04) :384-394

[4] Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies [J].

Al-Mansour, Zeina ;

Nelson, Beverly P. ;

Evens, Andrew M. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (03) :173-183

[5] The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review [J].

AlDabbagh, M. A. ;

Gitman, M. R. ;

Kumar, D. ;

Humar, A. ;

Rotstein, C. ;

Husain, S. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (03) :770-781

[6] Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus [J].

Allice, Tiziano ;

Busca, Alessandro ;

Locatelli, Franco ;

Falda, Michele ;

Pittaluga, Fabrizia ;

Ghisetti, Valeria .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (03) :600-608

[7] Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation [J].

Ambrose, T. ;

Sharkey, L. M. ;

Louis-Auguste, J. ;

Rutter, C. S. ;

Duncan, S. ;

English, S. ;

Gkrania-Klotsas, E. ;

Carmichae, A. ;

Woodward, J. M. ;

Russell, N. ;

Massey, D. ;

Butler, A. ;

Middleton, S. .

TRANSPLANTATION PROCEEDINGS, 2016, 48 (02) :492-496

[8] Allo-HLA reactivity of virus-specific memory T cells is common [J].

Amir, Avital L. ;

D'Orsogna, Lloyd J. A. ;

Roelen, Dave L. ;

van Loenen, Marleen M. ;

Hagedoorn, Renate S. ;

de Boer, Renate ;

van der Hoorn, Menno A. W. G. ;

Kester, Michel G. D. ;

Doxiadis, Ilias I. N. ;

Falkenburg, J. H. Frederik ;

Claas, Frans H. J. ;

Heemskerk, Mirjam H. M. .

BLOOD, 2010, 115 (15) :3146-3157

[9] CD154-expressing CMV-specific T cells associate with freedom from DNAemia and may be protective in seronegative recipients after liver or intestine transplantation [J].

Ashokkumar, Chethan ;

Green, Michael ;

Soltys, Kyle ;

Michaels, Marian ;

Mazariegos, George ;

Reyes-Mugica, Miguel ;

Higgs, Brandon W. ;

Spishock, Brianna ;

Zaccagnini, Madison ;

Sethi, Pradeep ;

Rzempoluch, Alexis ;

Kepler, Alexandra ;

Kachmar, Pam ;

Remaley, Lisa ;

Winnier, Julia ;

Jones, Katie ;

Moir, Kayla ;

Fazzolare, Tamara ;

Jenkins, Katherine ;

Hartle, Tara ;

Falik, Rachel ;

Ningappa, Mylarappa ;

Bond, Geoffrey ;

Khanna, Ajai ;

Ganoza, Armando ;

Sun, Qing ;

Sindhi, Rakesh .

PEDIATRIC TRANSPLANTATION, 2020, 24 (01)

[10]

Aslani HR, 2017, IRAN J PHARM RES, V16, P802

← 1 2 3 4 5 6 7 8 9 10 →